Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice

Matonti, F.; Meyer, Frank; Guigou, S.; Barthelemy, Tony; Dumas, Stéphane; Gobert, Frédéric; Hajjar, Christian; Merite, Pierre Yves; Parrat, Éric; Rouhette, H; Pommier, S.

doi:10.1111/aos.12190

Cited by 22 publications

(14 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…]The extended-release system Novadur® allows maintaining efficacy beyond the fourth month with a single injection. These results are consistent with the experience in retinal vein occlusions with a mean reinjection period of 5.4 months [9]. This long half-life is particularly suitable for a population of patients with diabetes who are less compliant.…”

Section: Discussionsupporting

confidence: 89%

Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema

Guigou¹,

Pommier²,

Meyer³

et al. 2015

Ophthalmologica

Self Cite

View full text Add to dashboard Cite

Purpose: To evaluate the efficacy and safety of intravitreal implant of dexamethasone (Ozurdex®) in diabetic macular edema (DME). Methods: This was a retrospective multicenter noncomparative study. Seventy-eight patients with DME followed for at least 6 months were included (P1.5 Network). Best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP) and cataract progression were studied at baseline and then at 1, 2, 4 and 6 months. Results: The mean CRT decrease from baseline was 145.2 µm at 6 months. The mean BCVA improvement from baseline was 6.7 at 6 months. An increase in IOP was observed for 11.7% of patients, and all patients were managed by topical treatment. No glaucoma or cataract surgery was necessary, and no endophthalmitis was reported. Conclusions: One injection of Ozurdex has an anatomical and functional effectiveness for the treatment of DME. Side effects were rare and manageable in our practice.

show abstract

Section: Discussionsupporting

confidence: 89%

Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema

Guigou¹,

Pommier²,

Meyer³

et al. 2015

Ophthalmologica

Self Cite

View full text Add to dashboard Cite

show abstract

“…Efficacy and safety results observed in the GENEVA trial were confirmed by several smaller retrospective [88,89] and prospective studies [90]. …”

Section: Role Of Steroids In the Management Of Rvomentioning

confidence: 60%

Optimal Treatment of Retinal Vein Occlusion: Canadian Expert Consensus

et al. 2015

View full text Add to dashboard Cite

Background: The availability of new therapeutic approaches, particularly intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapies, has prompted significant changes to the established treatment paradigms for retinal vein occlusion (RVO). Better visual outcomes and significantly lower rates of adverse events have been noted in multiple large randomized clinical trials and have led to a new standard of care for this sight-threatening condition. Objective: To develop an expert consensus for the management of RVO and associated complications in the context of recent clinical evidence. Methods: The development of a Canadian expert consensus for optimal treatment began with a review of clinical evidence, daily practice, and existing treatment guidelines and algorithms. The expert clinicians (11 Canadian retina specialists) met on February 1, 2014, in Toronto to discuss their findings and to propose strategies for consensus. Results: The result of this expert panel is a consensus proposal for Canadian ophthalmologists and retina specialists treating patients presenting with RVO. Treatment algorithms specific to branch and central RVO (BRVO and CRVO) were also developed. Conclusions: The consensus provides guidelines to aid clinicians in managing RVO and associated complications in their daily practice. In summary, laser remains the therapy of choice when neovascularization secondary to RVO is detected. Adjunctive anti-VEGF could be considered in managing neovascularization secondary to RVO in cases of vitreous hemorrhage. Intravitreal anti-VEGF should be considered for symptomatic visual loss associated with center-involving macular edema on optical coherence tomography. Patients with BRVO and a suboptimal response to anti-VEGF could be treated with grid laser, and those with CRVO and an inadequate response to anti-VEGF may be candidates for intravitreal steroids.

show abstract

“…This is an observational, retrospective, noncomparative, multicenter study, including a subset of the 220 patients with RVO treated by Ozurdex ® (Allergan) in the REMIDO study [8] . Seven…”

Section: Methodsmentioning

confidence: 99%

“…The functional endpoint was improvement of at least 15 letters in BCVA during visits before each IVT and 3 months after each IVT, compared to the baseline visit [8] . We reported 2 complementary measures of BVCA improvement.…”

Section: Study Endpointsmentioning

confidence: 99%

Long-Term Real-Life Efficacy and Safety of Repeated Ozurdex® Injections and Factors Associated with Macular Edema Resolution after Retinal Vein Occlusion: The REMIDO 2 Study

Pommier¹,

Meyer²,

Guigou³

et al. 2016

Ophthalmologica

Self Cite

View full text Add to dashboard Cite

Purpose: The objective was to study long-term real-life efficacy and safety of repeated Ozurdex® injections and factors associated with macular edema (ME) resolution after retinal vein occlusion. Methods: Patients with ME after retinal vein occlusion, receiving Ozurdex®, were included to assess the following endpoints: visual acuity and central retinal thickness, retreatment, number of injections, side effects and ME resolution. ME resolution was defined as permanent discontinuation of intravitreal injections (IVTs) for at least 6 months after the last IVT. Results: A total of 94 eyes were included with an average of 2.6 IVTs (max 6 IVTs). 58.6% of patients gained ≥15 letters and 51.1% of patients showed ME resolution. Among the resolved patients, 64.6% were treatment-naïve, 60.4% had branch retinal vein occlusion, and 78.1% gained ≥15 letters. Conclusions: Ozurdex® seemed to be a valuable treatment which may allow to achieve long-term anatomical and functional improvements and ME resolution with a minimum number of IVTs.

show abstract

Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice

Cited by 22 publications

References 4 publications

Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema

Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema

Optimal Treatment of Retinal Vein Occlusion: Canadian Expert Consensus

Long-Term Real-Life Efficacy and Safety of Repeated Ozurdex® Injections and Factors Associated with Macular Edema Resolution after Retinal Vein Occlusion: The REMIDO 2 Study

Contact Info

Product

Resources

About